Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19
Phase 1
Terminated
- Conditions
- Acute Respiratory Distress Syndrome
- Interventions
- Drug: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)Drug: Wharton's jelly derived Mesenchymal stem cells.
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- BioXcellerator
- Target Recruit Count
- 6
- Registration Number
- NCT04390152
- Locations
- 🇨🇴
BioXcellerator, Medellin, Antioquia-CO, Colombia
🇨🇴Clinical Somer, Rionegro, Antioquia, Colombia
News
No news found